Body Mass Index, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk
- PMID: 37814889
- PMCID: PMC10578703
- DOI: 10.1161/CIRCRESAHA.123.322762
Body Mass Index, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk
Abstract
Background: Obesity is a well-established risk factor for both adverse pregnancy outcomes (APOs) and cardiovascular disease (CVD). However, it is not known whether APOs are mediators or markers of the obesity-CVD relationship. This study examined the association between body mass index, APOs, and postpartum CVD risk factors.
Methods: The sample included adults from the nuMoM2b (Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-To-Be) Heart Health Study who were enrolled in their first trimester (6 weeks-13 weeks 6 days gestation) from 8 United States sites. Participants had a follow-up visit at 3.7 years postpartum. APOs, which included hypertensive disorders of pregnancy, preterm birth, small-for-gestational-age birth, and gestational diabetes, were centrally adjudicated. Mediation analyses estimated the association between early pregnancy body mass index and postpartum CVD risk factors (hypertension, hyperlipidemia, and diabetes) and the proportion mediated by each APO adjusted for demographics and baseline health behaviors, psychosocial stressors, and CVD risk factor levels.
Results: Among 4216 participants enrolled, mean±SD maternal age was 27±6 years. Early pregnancy prevalence of overweight was 25%, and obesity was 22%. Hypertensive disorders of pregnancy occurred in 15%, preterm birth in 8%, small-for-gestational-age birth in 11%, and gestational diabetes in 4%. Early pregnancy obesity, compared with normal body mass index, was associated with significantly higher incidence of postpartum hypertension (adjusted odds ratio, 1.14 [95% CI, 1.10-1.18]), hyperlipidemia (1.11 [95% CI, 1.08-1.14]), and diabetes (1.03 [95% CI, 1.01-1.04]) even after adjustment for baseline CVD risk factor levels. APOs were associated with higher incidence of postpartum hypertension (1.97 [95% CI, 1.61-2.40]) and hyperlipidemia (1.31 [95% CI, 1.03-1.67]). Hypertensive disorders of pregnancy mediated a small proportion of the association between obesity and incident hypertension (13% [11%-15%]) and did not mediate associations with incident hyperlipidemia or diabetes. There was no significant mediation by preterm birth or small-for-gestational-age birth.
Conclusions: There was heterogeneity across APO subtypes in their association with postpartum CVD risk factors and mediation of the association between early pregnancy obesity and postpartum CVD risk factors. However, only a small or nonsignificant proportion of the association between obesity and CVD risk factors was mediated by any of the APOs, suggesting APOs are a marker of prepregnancy CVD risk and not a predominant cause of postpartum CVD risk.
Keywords: body mass index; cardiovascular diseases; hypertension; obesity; pregnancy.
Conflict of interest statement
Figures


Comment in
-
Does Obesity Explain Cardiovascular Risk due to Adverse Pregnancy Outcomes?Circ Res. 2023 Oct 13;133(9):736-738. doi: 10.1161/CIRCRESAHA.123.323540. Epub 2023 Oct 12. Circ Res. 2023. PMID: 37824605 Free PMC article. No abstract available.
References
-
- Martin JA, Hamilton BE, Osterman MJ, Driscoll AK. Births: Final data for 2018. 2019. - PubMed
-
- Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circulation research. 2019;124:1094–1112. - PubMed
-
- Benton SJ, Leavey K, Grynspan D, Cox BJ, Bainbridge SA. The clinical heterogeneity of preeclampsia is related to both placental gene expression and placental histopathology. American Journal of Obstetrics and Gynecology. 2018;219:604. e601–604. e625. - PubMed
Publication types
MeSH terms
Grants and funding
- U10 HL120018/HL/NHLBI NIH HHS/United States
- U10 HD063037/HD/NICHD NIH HHS/United States
- K23 HL153667/HL/NHLBI NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- U01 HL145358/HL/NHLBI NIH HHS/United States
- U10 HL119993/HL/NHLBI NIH HHS/United States
- U10 HL119992/HL/NHLBI NIH HHS/United States
- U10 HD063053/HD/NICHD NIH HHS/United States
- U10 HL120019/HL/NHLBI NIH HHS/United States
- U10 HL120006/HL/NHLBI NIH HHS/United States
- R01 HL161514/HL/NHLBI NIH HHS/United States
- U10 HL119991/HL/NHLBI NIH HHS/United States
- R01 NS122815/NS/NINDS NIH HHS/United States
- U10 HD063036/HD/NICHD NIH HHS/United States
- U10 HL119989/HL/NHLBI NIH HHS/United States
- U10 HD063046/HD/NICHD NIH HHS/United States
- U10 HD063072/HD/NICHD NIH HHS/United States
- U10 HD063048/HD/NICHD NIH HHS/United States
- K23 NS107645/NS/NINDS NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- U10 HD063047/HD/NICHD NIH HHS/United States
- U10 HL119990/HL/NHLBI NIH HHS/United States
- UL1 TR001108/TR/NCATS NIH HHS/United States
- K23 HL159316/HL/NHLBI NIH HHS/United States
- U10 HD063041/HD/NICHD NIH HHS/United States
- U10 HD063020/HD/NICHD NIH HHS/United States
- UL1 TR000153/TR/NCATS NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- U10 HL120034/HL/NHLBI NIH HHS/United States